^
Association details:
| Biomarker: | KRAS Y96D |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Krazati (adagrasib) (KRAS G12C inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments
Published date:
05/07/2021
Excerpt:
142 Ba/F3 clones resistant to either sotorasib or adagrasib, of which 124 (87%) harbored secondary KRAS mutations. There were 12 different secondary KRAS mutations. Y96D/S was resistant to both inhibitors. A combination of novel SOS1 inhibitor, BI-3406, and trametinib showed potent activity against this resistance. While G13D, R68M and A59S/T which were highly resistant to sotorasib remained sensitive to adagrasib, Q99L was resistant to adagrasib but sensitive to sotorasib.
DOI:
https://doi.org/10.1016/j.jtho.2021.04.015
